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Abstract
Background: Myocardin is thought to have a key role in smooth muscle cell (SMC) development by acting on CArG-
dependent genes. However, it is unclear whether myocardin-induced SMC maturation and increases in agonist-induced
calcium signalling are also associated with increases in the expression of non-CArG-dependent SMC-specific genes.
Moreover, it is unknown whether myocardin promotes SMC development from human embryonic stem cells.
Methodology/Principal: Findings The effects of adenoviral-mediated myocardin overexpression on SMC development in
human ESC-derived embryoid bodies were investigated using immunofluorescence, flow cytometry and real time RT-PCR.
Myocardin overexpression from day 10 to day 28 of embryoid body differentiation increased the number of smooth muscle
a-actin+ and smooth muscle myosin heavy chain+ SMC-like cells and increased carbachol-induced contractile function.
However, myocardin was found to selectively regulate only CArG-dependent SMC-specific genes. Nevertheless, myocardin
expression appeared to be sufficient to specify the SMC lineage.
Conclusions/Significance: Myocardin increases the development and maturation of SMC-like cells from human embryonic
stem cells despite not activating the full repertoire of SMC genes. These findings have implications for vascular tissue
engineering and other applications requiring large numbers of functional SMCs.
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Introduction
Myocardin was originally identified as a serum response factor
(SRF) co-factor expressed only in cardiomyocytes and smooth
muscle cells (SMCs) [1]. Myocardin increases activation of SRF-
dependent genes by forming a higher order complex with SRF
and facilitating its association with its CArG box DNA binding
domain. Transcriptional activation is promoted by a variety of
mechanisms including myocardin’s own powerful transcriptional
activation domain [1] as well as recruitment of histone acetyl
transferases [2] and histone demethylases [3]. We and others have
shown that myocardin was required for SMC specific gene
expression, such that an increase in myocardin expression
upregulated SMC genes while a dominant negative form or knock
down of endogenous myocardin decreased SMC gene expression
[4–6]. Subsequently, it was demonstrated that a myocardin null
mouse died at mid-gestation and lacked SMC around the
developing dorsal aorta [7]. These and other findings led some
investigators to dub myocardin as a SMC ‘master-regulator’ [8].
However, further studies using myocardin null mouse embryonic
stem cells (ESCs) differentiated in vitro or injected into wild-type
blastocysts [9,10] have demonstrated that some SMCs are able to
develop in the absence of myocardin and that there is a tissue
specific requirement for myocardin in different SMC regions.
Other studies have also investigated the role of myocardin in
SMC development and whether overexpression of this transcrip-
tion factor led to SMC lineage commitment. Yoshida and
colleagues [11] demonstrated that forced expression of myocardin
in a variety of cell lines only increased CArG-box dependent SMC
genes, with no effect on non-CArG dependent SMC genes such as
smoothelin-B, focal adhesion kinase-related nonkinase (FRNK)
and aortic carboxypeptidase-like protein (ACLP) suggesting that
myocardin was not able to direct the full repertoire of activity
required for SMC development. The progenitor cells used in this
study included the P19-derived A404 SMC progenitor cells and
10T1/2 cells. Notably, neither of these cells have been shown to
exhibit contraction on assuming a SMC-like phenotype so it is
unclear to what extent they represent normal developmental
events. Murine ES cells were also transduced with myocardin.
These can generate contractile SMCs on differentiation in an
embryoid body [12], but were not differentiated using this protocol
in the study by Yoshida and colleagues [11]. Rat aortic SMCs
were also used although these cells generally lose their contractile
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properties rapidly in serum containing media. Consequently, it is
interesting to speculate whether cells already primed for, or
undergoing more physiological SMC differentiation would express
a wider range of SMC markers in response to myocardin given
that other key developmental regulators may already be present in
the cells. In contrast, Long and colleagues [13] suggested that
expression of myocardin alone in a BC3H1 myogenic precursor
line was sufficient to induce a SMC-like contractile phenotype, in
particular at the ultrastructural and functional levels. These latter
authors felt that myocardin was indeed functioning as a SMC
master regulator but did not specifically examine CArG versus
non-CArG genes. It is therefore unclear whether myocardin
increases SMC contractility and function despite failing to induce
non-CArG containing genes or whether cell types that show
increased contractility in response to myocardin also upregulate
the full repertoire of SMC genes.
Although SMC development has been studied in a wide range
of systems such as Xenopus, avian and mouse, the lack of suitable
models has limited the analysis of SMC development in man.
Human ESCs, however, offer the opportunity to determine
whether developmental mechanisms established in other species
also hold true in man. Although many molecular mechanisms and
pathways are conserved across species, there are examples in
which mouse and human systems diverge, such as the need for
leukaemia inhibitory factor (LIF) to maintain pluripotency in
mouse [14] but not human ESCs [15]. Moreover, efficient
methods to derive SMCs from human ESCs may potentially be
used in novel regenerative medicine applications such as
regeneration of the vessel wall as part of a therapeutic
revascularisation strategy for ischaemic tissues. In this context,
myocardin overexpression may represent a strategy for inducing
the SMC lineage and promoting SMC development with high
efficiency.
We examined whether overexpression of myocardin was able
to promote the formation of SMCs in differentiating human
embryoid bodies, whether contractile function in response to a
vaso-active agonist was affected and whether increased gene
expression was confined to the subset of CArG-dependent
genes.
Results
Development of SMC in Human Embryoid Bodies
Human ESC clumps were induced to undergo serum-induced
differentiation in embryoid bodies initially in suspension then
plated onto gelatin coated plates as described in the materials and
methods. This resulted in a dense outgrowth of differentiating cells
(marked by arrowheads in Fig. 1A) from the original embryoid
body. RNA was extracted from undifferentiated H9 human ESCs
(day 0) and from the embryoid bodies at days 15 and 28.
Quantitative RT-PCR studies showed increase in the expression of
a wide variety of SMC marker genes during differentiation
(Fig. 1B). There was considerable variability in the degree of
induction of key SMC marker genes; smooth muscle a-actin
(SMaA) and the cardiac marker cardiac troponin T (cTnT) were
highly expressed compared to the source hESC population
(Fig. 1C), while relatively small increases in the expression of
FRNK and the mature SMC marker, smooth muscle myosin
heavy chain (SMMHC) were detected.
Immunocytochemistry for SMaA and SMMHC at day 28
revealed the presence of groups of cells that stained for SMC
markers within the embryoid body outgrowth (Fig. 1D & E).
Consistent with the low level of SMMHC mRNA expression,
areas displaying SMMHC immunostaining were less frequent than
areas with SMaA immunostaining suggesting that the majority of
the SMCs in this system were developmentally immature. Under
the differentiation conditions used in this experiment, we have
previously seen spontaneous contraction of clusters of SMCs in
mouse embryoid bodies at approximately day 20 [16]. However,
spontaneous SMC-like contraction in human embryoid bodies was
not detected unless these were cultured for 45 days or more (data
not shown) suggesting a delay in SMC maturation in human
embryoid bodies compared to mouse under the present conditions.
Regulation of SMC Specific Markers and Cell Numbers in
Human Embryoid Bodies by Myocardin
To investigate whether exogenous myocardin would promote
SMC development, differentiating embryoid bodies were trans-
duced with adenoviruses expressing myocardin (Ad-Myo) or a
negative control, b-galactosidase (Ad-LacZ) at days 10, 14, 18 and
23, as described in the materials and methods. Since the embryoid
body is a multi-layered structure, viral transduction efficiency was
optimised using varying concentrations of Ad-LacZ; the optimal
dose of virus was chosen as 0.56107 pfu/ml (Fig. S1). Myocardin
overexpression was confirmed by immunoblotting of the Ad-Myo
transduced embryoid bodies (Fig. 2A). Expression levels were
lower at day 28 than at earlier time points, which may reflect
higher transduction efficiencies when embryoid bodies are smaller
as opposed to reduced adenovirus access to all cells in large densely
packed and multi-layered mature embryoid bodies.
Nevertheless, treatment with Ad-Myo resulted in a character-
istic change in morphology of some outgrowth regions in the
embryoid bodies, such that the cells appeared more spindle shaped
or ‘SMC-like’ (Fig. S2). Immunocytochemistry at day 28 revealed
areas with increased immunostaining for the SMC markers,
SMaA, SMMHC and calponin in response to myocardin
overexpression (Fig. 2B). SMMHC is a marker for mature SMCs
and raised the possibility that myocardin may promote the
development of a more mature SMC population.
In order to quantify SMC numbers, we carried out flow
cytometric analysis of SMaA and SMMHC expression on enzyme
dispersed embryoid bodies at day 17 and day 28 (Fig. 3).
Myocardin overexpression from day 10 onwards increased
numbers of SMaA+ cells versus the Ad-LacZ transduced negative
control (16.5% vs 10.5% at day 17 and 33.0% vs 15.1% at d28,
Fig. 3A & B). Similarly, the proportion of SMMHC+ cells
increased with Ad-Myo treatment (2.7% vs 0.6% at d17 and
25.7% vs 3.3% at d28, Fig. 3C & D). The low levels of SMMHC+
cells compared to SMaA+ cells confirm that at both day 17 and
day 28, untreated or Ad-LacZ treated embryoid bodies exhibit
SMCs that are relatively immature. However, in addition to
increasing the proportion of SMC-like cells in the embryoid body,
a major effect of myocardin is to promote maturation of these cells
as suggested by the great increase in the proportion of SMMHC+
cells by day 28. It should be noted that adenovirus infection by
itself resulted in a small increase in SMA+ and SMMHC+ cells
although there was always a clear effect of myocardin over the
virally delivered LacZ negative control.
An interesting observation is that although there was a
significant increase in SMaA mRNA during normal embryoid
body differentiation (Fig. 1C), in the no virus group the proportion
of SMaA+ cells was not significantly different between day 17 and
day 28 (9.3% vs 8.4% respectively, Fig. 3A). This discrepancy may
be accounted for by the significantly higher SMaA signal (median
signal in the SMaA+ group/median signal in SMaA2 group) at
day 28 relative to day 17 (Fig. 3E). Thus, while the number of
SMaA+ cells does not change between day 17 and day 28, their
SMaA content increases, possibly reflecting increased maturity.
Myocardin Promotes SMCs
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Myocardin Selectively Regulates CArG-dependent SMC
Genes
To examine the specific genes regulated by myocardin in
differentiating human embryoid bodies, we carried out quantita-
tive RT-PCR of both CArG-dependent and CArG-independent
SMC genes (Fig. 4). Expression of CArG-dependent SMC genes
such as SMaA, SM22a and SMMHC was significantly increased
by myocardin transduction while non-CArG dependent genes
such as smoothelin-B, FRNK and ACLP did not increase. These
data demonstrate that myocardin does not activate the full
repertoire of SMC genes in cells in differentiating human
embryoid bodies.
We also examined expression of markers of different germ layers
including nestin & PAX6 (ectoderm), SOX17 & FOXA2
(endoderm), Nkx2–5 & Isl1 (lateral plate mesoderm) and PAX1
& TCF15 (paraxial mesoderm) (Fig. S3A). Viral transduction and
myocardin overexpression had minimal effect on ectodermal or
endodermal markers. However, mesodermal markers showed
increase in expression with Ad-Myo compared to Ad-LacZ
transduction, although it appeared that viral transduction itself
may have reduced mesodermal marker expression (Ad-LacZ
compared to No virus). Nevertheless, while the changes in
mesodermal markers with myocardin overexpression were statis-
tically significant, the extent of the changes was greatly reduced
compared to those seen in CArG-dependent SMCmarkers (Fig. 4).
Finally, we also examined skeletal muscle and cardiac muscle gene
expression. Interestingly, myocardin did not regulate skeletal
muscle MHCs (MYH2 and MYH4) but did upregulate the cardiac
muscle genes, troponin T and alpha cardiac MHC.
Increased SMC Contractility with Myocardin
Overexpression
We then considered how incomplete activation of SMC genes
would impact upon SMC function. We initially examined Ca2+
concentration in the embryoid body and the response to a
vasoactive agonist, carbachol, as a measure of SMC function
and an estimate of contractile potential. Day 28 embryoid
bodies were dispersed into single cells and loaded with Fluo-4, a
Ca2+-sensitive fluorophore. Ca2+ influx in response to carbachol
was quantified by flow cytometry (Fig. 5). Treatment with Ad-
Myo resulted in a small increase in basal levels of intracellular
calcium compared to Ad-LacZ treated cells. Moreover, there
was a significantly greater increase in intracellular Ca2+ in
response to carbachol in Ad-Myo treated cells (mean Fluo-4
signal increased from 59.1 pre-carbachol to 86.8 post-carbachol,
a 47% increase) in comparison to the Ad-LacZ treated group
(55.6 pre-carbachol increased to 65.1 post-carbachol, a 17%
increase).
Figure 1. Development of SMCs in human embryoid bodies. (A) Low power dark field image of day 28 human embryoid body grown in 20%
FBS showing outgrowth of cells (white arrowheads) from the central embryoid body mass. (B and C) Expression of SMC specific genes in embryoid
bodies by real time RT-PCR at days 0, 15 and 28 is normalised by three housekeeping genes (GAPDH, UBC, 18S) and then presented relative to
undifferentiated human ESCs. RT-PCR data represent means from three independent experiments. Bars represent s.e.m. Cells that stain for SMaA (D)
and SMMHC (E) clearly seen at day 28 within embryoid bodies by immunofluorescence. Nuclei counterstained (blue) with DAPI. Bar in A= 1000 mm,
bars in D and E= 20 mm.
doi:10.1371/journal.pone.0044052.g001
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Next, we carried out direct measurements of SMC contractility
to assess the effects of myocardin overexpression. Day 28
embryoid bodies were enzymatically dispersed and the cells
reseeded in a collagen gel (Fig. 6). Gel contraction in response to
carbachol stimulation was significantly increased in the Ad-Myo
treated group (63% of starting area at 6 h and 31% at 18 h)
compared to either the Ad-LacZ group (86% and 62%) or the no
virus group (87% and 68%) (Fig. 6 A & B). In order to observe
SMC contraction at the individual cell level, we used an
alternative method of differentiating SMCs from hESCs using
defined growth factor combinations that we have recently
described [17]. Differentiating SMCs having undergone 12 days
of PDGF-BB and TGF-b1 treatment were treated with Ad-Myo or
Ad-LacZ. After 48 h, the proportion of SMCs contracting in
response to carbachol increased from 29% in the Ad-LacZ group
to 53% in the Ad-Myo treated group (p,0.01) (Fig. 6C and
Fig. S4A). In addition, there was a greater extent of individual cell
contraction in the myocardin treated group (20% reduction in
contractile cell surface area in the Ad-Myo treated group vs 7%
with Ad-LacZ (p,0.01) (Fig. S4B).
Together, these data make a compelling case that myocardin
overexpression increases hESC-derived SMC contractility. More-
over, myocardin is able to promote a phenotype that displays
functional properties consistent with a more mature contractile
phenotype without activating the entire repertoire of SMC genes.
Myocardin has an Early Dominant Effect in Developing
Cells
An intriguing question raised by our studies is whether
myocardin expression promotes the SMC phenotype in all
developing cells, ie affects lineage commitment or whether
myocardin simply promotes SMC maturation and contractility
in cells that are already committed to the SMC phenotype. Our
flow cytometry data show that even in the Ad-Myo treated group,
only a minority of cells ultimately expressed SMC markers whilst a
large proportion remained SMaA and SMMHC negative. To
determine whether these SMC marker-negative cells were a result
of low Ad-Myo transduction efficiency or the inability of
myocardin to promote the SMC lineage in all developing cells,
we carried out flow cytometry with co-labelling for the FLAG tag
Figure 2. Myocardin overexpression increases SMaA, calponin and SMMHC staining. Immunoblotting of embryoid bodies transduced
with Ad-LacZ or Ad-Myo confirm myocardin overexpression at a variety of developmental times (A). Immunofluorescent assessment of day 28
embryoid bodies reveals an increase in SMaA, calponin and SMMHC (B) staining following treatment with Ad-Myo from day 10 onwards, in
comparison to no treatment or Ad-LacZ negative controls. Photomicrograph exposure times were kept constant across all three treatment groups
and deliberately low enough to clearly show the large increases in fluorescent intensity in the Ad-Myo group. Nuclei counterstained (blue) with DAPI.
Bar = 100 mm.
doi:10.1371/journal.pone.0044052.g002
Myocardin Promotes SMCs
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on the myocardin transgene and SMMHC (Fig. 7). The low
proportion of day 28 cells (12%) that were FLAG+ implies that
transduction efficiency was still a limitation on the ability to
generate SMC-like cells. Interestingly, flow cytometric analysis of
less well differentiated embryoid bodies (day 21) suggested that
transduction efficiency and myocardin expression were higher at
earlier stages of differentiation (16.6% FLAG+), likely due to
greater viral access to cells in smaller less compact embryoid
bodies (Fig. S5). In any case, the majority (88–90%) of transduced,
FLAG expressing cells also expressed the specific SMC marker
SMMHC, suggesting that myocardin has a dominant role in SMC
lineage commitment.
We also investigated whether timing of adenoviral delivery
was important and compared induction of SMC marker positive
populations by flow cytometry when embryoid body transduc-
tion was carried out early (day 10 or days 10 & 14) or late (days
18 & 23) or throughout differentiation (days 10, 14, 18 & 23)
(Fig. 8). We found that the number of SMaA+ cells was
significantly reduced in the late transduction group (days 18 &
23) compared to transduction throughout differentiation
(p,0.05). However, early transduction alone (day 10 or days
Figure 3. Myocardin overexpression increases number of SMC-like cells. Embryoid bodies were enzymatically dispersed into single cells at
day 17 or day 28 and flow cytometric assessment for SMC markers was carried out. Groups that had been treated with no virus, Ad-LacZ or Ad-Myo
from day 10 onwards were used to quantify the proportion of SMaA+ cells (A & B) and SMMHC+ cells (C & D). Both FL1 and FL2 channels were
measured for all samples to distinguish specific signal for SMaA (FL1 in A) and SMMHC (FL2 in B) due to the high levels of autofluorescence in
embryoid body-derived cells. In the no virus group, SMaA staining was quantified as median SMaA+ signal/median SMaA2 signal at both day 17 and
day 28 (E). Data presented in A and C are representative flow cytometric plots from a single study with the means from three independent
experiments specified in the gated regions and as bar charts 6 s.e.m. (B, D & E). **p,0.01.
doi:10.1371/journal.pone.0044052.g003
Myocardin Promotes SMCs
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10 & 14) was not detrimental to SMC induction and generated
comparable SMaA+ cells to transduction throughout. Interest-
ingly, SMMHC which is a late SMC marker and as such
correlates well with maturation was not significantly different
regardless of timing of viral transduction. These data are
consistent with a role for myocardin in SMC induction or
lineage determination early on in development alongside a role
in promoting a mature SMC in later development.
Discussion
We have demonstrated that myocardin overexpression in
human embryoid bodies upregulates the subset of SMC genes
that are CArG-dependent and is not able to activate the full SMC
developmental program. These results extend the findings of
Yoshida and colleagues [11] to SMC development in a human
system in which contractile SMCs normally develop. Thus
although non-CArG dependent genes such as smoothelin or
ACLP are expressed in the embryoid body system, there is no
increase in their expression in response to myocardin overexpres-
sion in contrast to the dramatic increase in expression of CArG-
dependent genes such as SMaA, SM22a and SMMHC. In
contrast, Long and colleagues [13] reported that myocardin
promoted the development of SMC-like cells when overexpressed
in a BC3H1 myogenic cell line. This study only reported on
expression of CArG-dependent marker genes and did not
investigate changes in non-CArG dependent genes. Thus,
although the transduced BC3H1 cells showed contractile respons-
es to KCl, it wasn’t clear whether the cells fully took on a
contractile SMC phenotype as specific SMC agonists such as
angiotensin II or carbachol were not tested. In our study, although
only CArG-dependent genes were activated, myocardin overex-
pression did result in greater Ca2+ currents in response to
carbachol and increased SMC contraction suggesting that
myocardin did indeed promote a more mature contractile SMC
phenotype.
The SMCs that develop using the described embryoid body
protocol, in the absence of exogenous myocardin, appear to be
relatively immature given the low expression of SMMHC and the
lack of spontaneous SMC-like contraction by day 28. Other
groups have reported higher efficiencies of SMC induction from
human ESCs, for example Huang and colleagues [18] reported
highly efficient induction of contractile SMCs (94.5% SMaA+
cells) using retinoic acid induction on monolayer cultures.
However the high concentration of retinoic acid (10 mM) used
by Huang and colleagues raises questions as to the physiological
nature of the subsequent SMC induction. Indeed, one of the
advantages of our embryoid body approach is that it is thought to
replicate some aspects of embryonic development such as the
generation of cells corresponding to the embryonic germ layers
and heterotypic cell-cell and cell-matrix interactions, and poten-
tially offers a more ‘physiological’ system for investigating
development [12]. Moreover, while SMC maturation could be
accelerated by further manipulation of the culture conditions, the
current protocol is entirely suitable for the purposes of a
myocardin gain of function study.
When assessing SMC development and identity, in addition to a
range of SMC markers it is essential to measure SMC function.
Thus, a particular strength of this study is that the effects of
myocardin on hESC-derived SMC contractile function have been
evaluated in a variety of different ways. We chose to examine Ca2+
influx secondary to vasoactive drugs as this is usually a prerequisite
for SMC contraction and also directly measured contraction in
seeded collagen gels. Moreover, we used a novel chemically-
defined in vitro system that we have recently described to visualise
the contraction of individual SMCs. These multiple lines of
evidence strongly suggested that myocardin overexpression
promotes a contractile phenotype in human ESC-derived SMCs.
This may be of importance in regenerative medicine applications
where mature contractile SMCs are required [19].
It is instructive to examine the pattern of gene regulation
associated with myocardin overexpression in developing human
Figure 4. Selective upregulation of CArG-dependent genes by myocardin. Embryoid bodies were treated with no virus, Ad-LacZ or Ad-Myo
from day 10 to day 28 and then harvested for RNA. SMC marker expression for a range of CArG-dependent and non-dependent genes was measured
using real time RT-PCR and is normalised by three housekeeping genes and then presented relative to no virus controls. RT-PCR data represent
means from at least three independent experiments. Error bars represent s.e.m. SMaA and SMMHC expression levels in response to myocardin were
significantly higher than the other genes and thus the precise levels are depicted by numbers above the black bars (6 s.e.m.).
doi:10.1371/journal.pone.0044052.g004
Myocardin Promotes SMCs
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Figure 5. Myocardin promotes calcium influx in response to carbachol. Embryoid bodies were treated with Ad-LacZ or Ad-Myo from day 10
to day 28 and then dispersed into a single cell suspension. Cells were loaded with Fluo-4, a calcium sensitive fluorophore, and intracellular [Ca2+] was
measured by flow cytometry before and after the addition of the muscarinic agonist, carbachol in arbitrary units (AU). Representative data from a
single experiment (A) and means of three studies (B) show significant increases in fluorescence following addition of carbachol. Error bars represent
s.e.m., ns = not significant, * = p,0.05, C = carbachol.
doi:10.1371/journal.pone.0044052.g005
Myocardin Promotes SMCs
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embryoid bodies. The most striking feature is a dramatic
upregulation of CArG-dependent SMC genes, consistent with
myocardin’s known mechanism of action through promoting SRF-
CArG box interactions [1,4,5,6]. Consistent with previous studies
by Yoshida and colleagues [11] and Long and colleagues [13],
increased expression of cardiac muscle markers was also seen. Of
note, there was no increase in skeletal muscle markers and
previous studies have demonstrated that myocardin has a
dominant effect favouring SMC induction over skeletal muscle
in developing somites [20]. An important question to consider is
how is SMC contractility increased when the predominant effect is
on the subset of genes that are CArG-dependent? A relevant factor
may be that other (non-CArG-dependent) genes required for
contraction are also being induced in the developing embryoid
body. We hypothesise that cells may be ‘primed’ for acquiring
contractile function and this process is accelerated by the CArG-
dependent upregulation of SMC contractile genes. It should be
noted however that some non-CArG-dependent SMC genes such
as smoothelin B and a number of mesodermal markers also show
modest increases in expression and importantly non-CArG-
dependent mechanisms of action of myocardin have been
previously described [21].
A key question is whether myocardin promotes commitment to
the SMC lineage in uncommitted multipotent cells in the
embryoid body or whether it acts only to accelerate/promote
SMC maturation once precursor cells have already undergone
specification. Previous studies have shown that in A404 cells, the
expression of at least a low level of myocardin is associated with
the ability of these cells to form SMCs efficiently in contrast to the
parental P19 line which does not express myocardin and does not
form SMC at high frequency [11]. It has also been reported that
myocardin expression has a dominant effect on skeletal muscle
progenitors [20]. In the present study, although the majority of
cells in Ad-Myo treated embryoid bodies did not express SMC
markers, co-localisation with FLAG demonstrated that these cells
were likely not transduced, possibly due to inefficiencies with viral
transduction given the complex layering and compact three-
dimensional structure of the embryoid body. In fact, the vast
majority of cells that expressed the FLAG tag also expressed the
highly specific SMC marker, SMMHC, suggesting that myocardin
does indeed have a dominant effect on a wide variety of cells in the
developing human embryoid body.
Further analyses on timing of transgene delivery suggest that
early transduction is important for SMC lineage determination,
with reduced induction of SMaA+ cells with late transduction only.
In keeping with this, adenoviral delivery timing did not influence
numbers of SMMHC+ cells, perhaps since this marker reflects
maturation better than lineage induction (as immature SMCs may
be SMaA+ yet SMMHC2). It is recognised that a limitation of the
experiments presented is the sub-optimal adenoviral transduction
of embryoid bodies, likely due to the multilayered nature of these
structures, which may dilute the experimental effects of myocar-
din. One possibility for further experiments would be to generate
an inducible myocardin system with lentiviral delivery prior to
embryoid body formation, which would result in transgene
integration into the host genome and may lead to more effective
transgene expression. For the purposes of this study, we have
focussed exclusively on myocardin gain of function. Studies in the
mouse using myocardin-null ESCs [9,10] have suggested that
myocardin may not be absolutely required for SMC development,
possibly due to redundant mechanisms. Further studies in human
ESCs using a loss of function approach are indicated to clarify the
role of myocardin in human SMC development and determine the
basis of any possible redundancy.
In conclusion, these studies demonstrate that myocardin
overexpression was able to promote the formation and maturation
of SMC-like cells in differentiating human embryoid bodies in a
dominant manner despite increased gene expression being
predominantly confined to the subset of CArG-dependent genes.
These findings have implications for vascular tissue engineering
Figure 6. Contractile phenotype is promoted by myocardin overexpression. Embryoid bodies were treated with Ad-LacZ or Ad-Myo from
day 10 to day 28, dispersed into a single cell suspension and seeded into collagen gels in 24 well plates (A). Gel contraction in response to carbachol
was significantly increased in the Ad-myo group (B). Data points represent the means (6s.e.m.) of three experiments. SMCs derived from human ESCs
using a 2-dimensional culture protocol were individually examined for contraction following transduction with Ad-LacZ or Ad-Myo using time lapse
microscopy. Percentage of contractile cells increased from 29% with Ad-LacZ to 53% with Ad-Myo (C). Results represent the mean values (6s.e.m.)
from 10 randomly chosen optical fields. **p,0.01.
doi:10.1371/journal.pone.0044052.g006
Myocardin Promotes SMCs
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Human H9 ESCs were obtained from Wicell (Madison,
Wisconsin) and cultured on irradiated mouse embryonic fibro-
blasts (MEFs) using KSR medium [advanced DMEM/F12 (Life
Sciences), 20% knockout serum replacer (Life Sciences), 2 mM L-
glutamine and 0.1 mM b-mercaptoethanol] supplemented with
4 ng/ml FGF-2 (R&D Systems) or on gelatin coated plates using
chemically defined media (CDM) [IMDM and F12 (1:1 mix),
5 mg/ml bovine serum albumin (BSA, Sigma), 1% lipid concen-
trate (Life Sciences), 450 mM monothioglycerol (Sigma), 7 mg/ml
insulin (Roche) and 15 mg/ml transferrin (Roche)] supplemented
with 10 ng/ml Actinic A (R&D Systems) and 12 ng/ml FGF-2.
ESC colonies were passaged by a brief treatment with 1 mg/ml
collagenase IV (dissolved in advanced DMEM/F12, 20% KSR
and 2 mM L-glutamine) and then mechanically scraped using a
5 ml pipette. ESC clumps were washed with PBS and replated or
cultured in suspension in embryoid body medium [DMEM high
glucose (Life Sciences), 20% foetal bovine serum, 0.1 mM non-
essential amino acids, 1 mM pyruvate and 1% penicillin-
streptomycin-glutamine (Life Sciences)] to generate embryoid
bodies. As previously described for mouse ESCs [16], embryoid
bodies were plated onto gelatin coated plates at day 6 to allow
attachment and then treated with 10 nM all trans-retinoic acid
(atRA, Sigma) from d7-d10. Embryoid bodies were harvested at
varying time-points for RNA or dispersed with collagenase and
elastase [1 mg/ml collagenase type 2, 0.75 u/ml porcine elastase
and 1 mg/ml soya bean trypsin inhibitor (all from Worthington
Biochem Corp) in PBS] then fixed in BD Cytofix/Cytoperm
solution (BD Biosciences) for 15 min at 4uC prior to flow
cytometric analysis.
Two-dimensional human ESC differentiation was carried out as
described previously [17]. Briefly, human ESCs were induced to a
mesodermal fate using FGF-2, BMP-4 and LY294002 for 36 h
then FGF-2 and BMP-4 for a further 3.5 days. Cells were then
treated with PDGF-BB and TGF-b1 for 12 days to generate
contractile SMCs.
Adenoviruses
Replication deficient adenoviruses encoding either b-galactosi-
dase (Ad-LacZ) or myocardin (Ad-Myo) were generated using
standard methods by the University of Iowa Gene Transfer Vector
Core [6,22] and obtained with the approval of Dr GK Owens
(University of Virginia, USA). Embryoid bodies were transduced
using the adenoviruses on days 10, 14, 18 and 23 of differentiation.
Optimum virus concentration for maximising transduction
efficiency was estimated by titrating the Ad-LacZ concentration
(Figure S1) and a concentration of 0.56107 pfu/ml was used for
these studies and applied overnight.
Real Time RTPCR
RNA was extracted using Trizol (Life Sciences) according to the
manufacturer’s instructions and cDNA was synthesised using the
Superscript III kit (Life Sciences). Quantitative PCR was carried
out using the SYBR Green PCR Master Mix (Applied Biosystems)
in a Rotor Gene 6000 (Corbett). A full list of primers can be found
in table 1. A reference standard curve was included with every run
and all genes were normalised to the geometric mean of three
reference genes [23]: glyceraldehydes-3-phosphate dehydrogenase
(GAPDH), ubiquitin C (UBC) and 18S. Data in bar graphs are
presented as mean 6 s.e.m. of 3 independent experiments.
Immunofluorescence and x-gal Staining
Embryoid bodies were fixed in 4% paraformaldehyde and then
permeabilised with 0.2% triton in PBS. Specimens were blocked
with 3% BSA and then the following primary antibodies were
used: anti-SMaA (Sigma, A2547) at 1:1000 and anti-SMMHC
(Sigma, M7786) at 1:2000. Anti-mouse or anti-rabbit secondaries
labelled with Alexa Fluor 568 (Life Sciences) were used at 1:400
Figure 7. Myocardin has a dominant instructive role on development of SMC-like cells in the embryoid body. Embryoid bodies were
treated with Ad-LacZ or Ad-Myo from day 10 to day 28 then dispersed and fixed for flow cytometry. (A) The subset of cells transduced with the Ad-
Myo virus was identified by flow cytometric detection of the 39 FLAG tag fused to the myocardin transgene. (B) The effect of Ad-Myo treatment on
%SMMHC+ cells was analysed by flow cytometry. The majority (90%) of FLAG+ Ad-Myo transduced cells demonstrated a SMC-like phenotype. Data are
representative of three independent experiments.
doi:10.1371/journal.pone.0044052.g007
Figure 8. Timing of viral transduction reveals an early role in
SMC induction for myocardin. Embryoid bodies were transduced
with Ad-LacZ or Ad-Myo early (day 10 alone or days 10 & 14), late (days
18 & 23) or throughout differentiation (days 10, 14, 18 &13). Late
delivery of Ad-Myo reduced number of SMaA+ cells (A) (*p,0.05 by
ANOVA and Tukey HSD) but had no significant effect on SMMHC+ cell
numbers (B). Values represent mean cell proportions from three
independent experiments (6 s.e.m.). *p,0.05.
doi:10.1371/journal.pone.0044052.g008
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and nuclei were counterstained with 0.5 mg/ml 49,6-diamidino-2-
phenylindole (DAPI). For x-gal staining, paraformaldehyde fixed
embryoid bodies were incubated overnight at 37uC with x-gal
staining solution (1 mg/ml x-gal, 5 mM potassium ferricyanide,
5 mM potassium ferrocyanide and 2 mM magnesium chloride in
PBS). Images were taken using a Zeiss Axiovert 200 M
microscope.
Flow Cytometry and Intracellular Calcium
Fixed single cell suspensions were blocked with 3% BSA and
then labelled with primary antibodies in BD Perm/Wash buffer
(BD Biosciences) as follows: anti-SMaA-FITC (Sigma, F3777) at
1:1000, anti-SMMHC (Sigma, M7786) at 1:500 and anti-FLAG-
PE (Abcam, ab72469) at 1:300. Anti-mouse-PE or anti-mouse
Alexa Fluor 647 secondaries (Life Sciences, 1:400) were used for
anti-SMMHC detection. Samples were analysed on a Cyan ADP
analyzer (Beckman Coulter). Both FL1 and FL2 channels were
measured for all samples to distinguish specific signal for SMaA
(FL1 in Fig. 3A) and SMMHC (FL2 in Fig. 3B) due to the high
levels of autofluorescence in embryoid body-derived cells. For the
calcium studies, an unfixed single cell suspension was isolated from
embryoid bodies as described above and loaded with 2.5 mM Fluo-
4 (Molecular Probes), a calcium sensitive fluorophore, for 1 hr at
37uC. Calcium influx was induced by the addition of 100 mM
carbachol (Sigma) and cellular [Ca2+] was estimated by fluores-
cence in the FL1 channel of the flow cytometer immediately prior
to, immediately post- and 1 min post- addition of carbachol. Data
presented are representative of 3 independent experiments.
Western Blot Analysis
Proteins were extracted using lysis buffer (10 mM Tris-HCl,
pH 7.6, 140 mM NaCl, 1 mM EDTA, 1% Triton X-100, pro-
tease and phosphatase inhibitor cocktail (Sigma)), and concentra-
tions determined using a BCA Protein Assay Kit (Thermo
Scientific). Samples were separated by SDS-PAGE and proteins
transferred on to polyvinylidene difluoride membranes, blocked in
5% milk in Tris-buffered saline and 0.05% Tween 20, incubated
with primary antibodies against myocardin (Sigma M8948; 1:1000
dilution) and b-actin (Sigma A2228; 1:10,000 dilution) followed by
incubation with horseradish peroxidase-conjugated secondary
antibodies (Dako). Signals were detected using ECL Western
Blotting Detection Reagents (GE Healthcare Life Sciences).
Contraction Assays
The collagen gel was prepared by mixing 8 parts of ice-cold
collagen Type-1 solution (Sigma Aldrich, UK) with 1 part of 106
PBS. The pH of the mixture was adjusted to 7.2–7.4. The cells
were resuspended at a density of 0.66106 cells/ml of collagen
mixture and 500 ml was pipetted into each well of a 24-well plate.
Gels were polymerised at 37uC 45–60 min. The contraction assay
was initiated by the addition of 50 mM of carbachol. The gel areas
were measured at 0, 6 & 18 hours of carbachol stimulation using
Image J software.
For assessment of individual cell contraction, SMCs were
generated using the two-dimensional directed differentiation
protocol. SMCs were transduced with Ad-LacZ or Ad-Myo and
examined for contractile responses by time-lapse microscopy 48 h
after viral transduction in response to 50 mM carbachol.
Statistics
Means between two groups were compared using the student’s
t-test. Multiple groups were compared using one way ANOVA
and differences between groups confirmed by Tukey HSD test.
Table 1. Primer sequences used for real time RT-PCR.
Gene Forward primer Reverse primer Annealing Temp (6C)
SMaA CACTGTCAGGAATCCTGTGA CAAAGCCGGCCTTACAGA 65
SM22a TCTTTGAAGGCAAAGACATGG TTATGCTCCTGCGCTTTCTT 65
SMMHC AGATGGTTCTGAGGAGGAAACG AAAACTGTAGAAAGTTGCTTATTCACT 65
Myocardin TGCAGCTCCAAATCCTCAGC TCAGTGGCGTTGAAGAAGAGTT 60
Smoothelin-B TGCCGAGGCCCAGTGCCTTA GGGTCCAGCCACGTCTGCTC 60
ACLP GGCATCGTCAACGGGGCCAA GCGGTGCACCTGCTCCATGA 60
FRNK TCGGCTTGGCCCTGAGGACA GGCGTGAGCAGCAGTCAGCA 60
cTnT GGAAGAGGCAGACTGAGCGGGA TCCCGCGGGTCTTGGAGACTT 60
UBC ATTTGGGTCGCGGTTCTTG TGCCTTGACATTCTCGATGGT 60
GAPDH AACAGCCTCAAGATCATCAGC GGATGATGTTCTGGAGAGCC 60
18S GACACGGACAGGATTGACAGATTG TGCCAGAGTCTCGTTCGTTATCG 60
Nestin GAAACAGCCATAGAGGGCAAA TGGTTTTCCAGAGTCTTCAGTGA 60
NKX2.5 CAAGTGTGCGTCTGCCTTT CAGCTCTTTCTTTTCGGCTCTA 60
ISL1 AGATTATATCAGGTTGTACGGGATCA ACACAGCGGAAACACTCGAT 60
FoxA2 GGGAGCGGTGAAGATGGA TCATGTTGCTCACGGAGGAGTA 60
Sox17 CGCACGGAATTTGAACAGTA GGATCAGGGACCTGTCACAC 60
PAX1 CACACTCGGTCAGCAACATC GGTTTCTCTAGCCCATTCACTG 60
TCF15 GCACCTTCTGCCTCAGCAACCAGC GGTCCCCCGGTCCCTACACAA 60
MYH2 AGCTCCAAGAACTGTCTCACTCCCA TGGGCCTCAATGCGCTCCCT 60
MYH4 TGTCTGCTTTGAGCCTGCCACC TTACAGTAGCTCCAGCTTCGGTCTT 60
doi:10.1371/journal.pone.0044052.t001
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Supporting Information
Figure S1 Optimisation of adenoviral titres for trans-
duction. Embryoid bodies were transduced using a range of Ad-
LacZ titres (0.56106 to 1.56107 pfu/ml) and then stained with X-
gal to identify optimal viral titres to ensure maximal transduction.
Bar = 100 mm.
(PDF)
Figure S2 Myocardin overexpression promotes a con-
tractile SMC appearance in embryoid bodies. Effects of
Ad-LacZ (A and C) or Ad-Myo (B and D) treatment from day 10
to day 28 on the appearance of cells in the embryoid body
outgrowth. Phase contrast images were taken at day 28.
Bar = 100 mm.
(PDF)
Figure S3 Mesoderm and cardiac genes are upregulated
by myocardin overexpression. Embryoid bodies were treated
with no virus, Ad-LacZ or Ad-Myo from day 10 to day 28 and
then harvested for RNA. Real time RT-PCR was used to quantify
markers of ectoderm, endoderm and mesoderm (A). Markers of
skeletal muscle (B) and cardiac muscle (C) were also investigated.
RT-PCR data represent means from three independent experi-
ments (6 s.e.m.). *p,0.05, **p,0.01.
(PDF)
Figure S4 Myocardin overexpression increases human
ESC-derived SMC contractility. Human ESCs were induced
to undergo differentiation on a 2-dimensional surface using
defined growth factors. Two days after Ad-LacZ or Ad-Myo
transduction, individual SMCs were visualised at 0 min and
15 min for contractile activity in response to carbachol stimula-
tion. The percentage change of cell surface area was determined
from 20 contracting cells selected randomly from 10 different
optical fields. (***p,0.001).
(PDF)
Figure S5 Reduced myocardin-FLAG transgene expres-
sion with embryoid body maturation. Embryoid bodies
were treated with Ad-LacZ or Ad-Myo from day 10 onwards and
dispersed and fixed for flow cytometry at day 21 (A–C) or day 28
(D–F). The subset of cells transduced with the Ad-Myo virus was
identified by flow cytometric detection of the 39 FLAG tag fused to
the myocardin transgene, which was higher at day 21 than day 28.
The effect of myocardin-FLAG transgene expression on
%SMMHC+ cells was analysed by flow cytometry. The majority




The authors acknowledge the excellent technical assistance of Ms Morgan
Alexander. We would also like to thank Dr Helle Jorgensen for critical
reading of the manuscript.
Author Contributions
Conceived and designed the experiments: SS AT CC. Performed the
experiments: LR SS AT CC. Analyzed the data: LR SS AT CC.
Contributed reagents/materials/analysis tools: SS AT CC. Wrote the
paper: SS AT CC.
References
1. Wang D, Chang PS, Wang Z, Sutherland L, Richardson JA, et al. (2001)
Activation of cardiac gene expression by myocardin, a transcriptional cofactor
for serum response factor. Cell 105: 851–862.
2. Cao D, Wang Z, Zhang CL, Oh J, Xing W, et al. (2005) Modulation of smooth
muscle gene expression by association of histone acetyltransferases and
deacetylases with myocardin. Mol Cell Biol 25: 364–376.
3. Lockman K, Taylor JM, Mack CP (2007) The histone demethylase, Jmjd1a,
interacts with the myocardin factors to regulate SMC differentiation marker
gene expression. Circ Res 101: e115–e123.
4. Chen J, Kitchen CM, Streb JW, Miano JM (2002) Myocardin: a component of a
molecular switch for smooth muscle differentiation. J Mol Cell Cardiol 34:
1345–1356.
5. Du KL, Ip HS, Li J, Chen M, Dandre F, et al. (2003) Myocardin is a critical
serum response factor cofactor in the transcriptional program regulating smooth
muscle cell differentiation. Mol Cell Biol 23: 2425–2437.
6. Yoshida T, Sinha S, Dandre´ F, Wamhoff BR, Hoofnagle MH, et al. (2003)
Myocardin is a key regulator of CArG-dependent transcription of multiple
smooth muscle marker genes. Circ Res 92: 856–864.
7. Li S, Wang DZ, Wang Z, Richardson JA, Olson EN (2003) The serum response
factor coactivator myocardin is required for vascular smooth muscle develop-
ment. Proc Natl Acad Sci U S A 100: 9366–9370.
8. Wang Z, Wang DZ, Pipes GC, Olson EN (2003) Myocardin is a master
regulator of smooth muscle gene expression. Proc Natl Acad Sci U S A 100:
7129–7134.
9. Pipes GC, Sinha S, Qi X, Zhu CH, Gallardo TD, et al. (2005) Stem cells and
their derivatives can bypass the requirement of myocardin for smooth muscle
gene expression. Dev Biol 288: 502–513.
10. Hoofnagle MH, Neppl RL, Berzin EL, Pipes GC, Olson EN, et al. (2011)
Myocardin is differentially required for the development of smooth muscle cells
and cardiomyocytes. Am J Physiol Heart Circ Physiol 300: H1707–H1721.
11. Yoshida T, Kawai-Kowase K, Owens GK (2004) Forced expression of
myocardin is not sufficient for induction of smooth muscle differentiation in
multipotential embryonic cells. Arterioscler Thromb Vasc Biol 24: 1596–1601.
12. Drab M, Haller H, Bychkov R, Erdmann B, Lindschau C, et al. (1997) From
totipotent embryonic stem cells to spontaneously contracting smooth muscle
cells: a retinoic acid and db-cAMP in vitro differentiation model. FASEB J 11:
905–915.
13. Long X, Bell RD, Gerthoffer WT, Zlokovic BV, Miano JM (2008) Myocardin is
sufficient for a smooth muscle-like contractile phenotype. Arterioscler Thromb
Vasc Biol 28: 1505–1510.
14. Smith AG, Heath JK, Donaldson DD, Wong GG, Moreau J, et al. (1988)
Inhibition of pluripotential embryonic stem cell differentiation by purified
polypeptides. Nature 336: 688–690.
15. Vallier L, Alexander M, Pedersen RA (2005) Activin/Nodal and FGF pathways
cooperate to maintain pluripotency of human embryonic stem cells. J Cell Sci
118: 4495–4509.
16. Sinha S, Hoofnagle MH, Kingston PA, McCanna ME, Owens GK (2004)
Transforming growth factor-beta1 signaling contributes to development of
smooth muscle cells from embryonic stem cells. Am J Physiol Cell Physiol 287:
C1560–C1568.
17. Cheung C, Bernardo AS, Trotter MW, Pedersen RA, Sinha S (2012)
Generation of human vascular smooth muscle subtypes provides insight into
embryological origin-dependent disease susceptibility. Nat Biotechnol. 30: 165–
73.
18. Huang H, Zhao X, Chen L, Xu C, Yao X, et al. (2006) Differentiation of human
embryonic stem cells into smooth muscle cells in adherent monolayer culture.
Biochem Biophys Res Commun 351: 321–327.
19. Cheung C, Sinha S (2011) Human embryonic stem cell-derived vascular smooth
muscle cells in therapeutic neovascularisation. J Mol Cell Cardiol 51: 651–64.
20. Long X, Creemers EE, Wang DZ, Olson EN, Miano JM (2007) Myocardin is a
bifunctional switch for smooth versus skeletal muscle differentiation. Proc Natl
Acad Sci U S A 104: 16570–16575.
21. Qiu P, Ritchie RP, Fu Z, Cao D, Cumming J, et al. (2005) Myocardin enhances
Smad3-mediated transforming growth factor-beta1 signaling in a CArG box-
independent manner: Smad-binding element is an important cis element for
SM22alpha transcription in vivo. Circ Res 97: 983–91.
22. Ooboshi H, Chu Y, Rios CD, Faraci FM, Davidson BL, et al. (1997) Altered
vascular function after adenovirus-mediated overexpression of endothelial nitric
oxide synthase. Am J Physiol 273: H265–H270.
23. Vandesompele J, De Preter K, Pattyn F, Poppe B, Van Roy N, et al. (2002)
Accurate normalization of real-time quantitative RT-PCR data by geometric
averaging of multiple internal control genes. Genome Biol 3: RESEARCH0034.
Myocardin Promotes SMCs
PLOS ONE | www.plosone.org 12 August 2012 | Volume 7 | Issue 8 | e44052
